CNS Penetrant definition

CNS Penetrant means (a) Rxxx, (b) any Rxxx Backup, (c) any compounds Covered by [*] that meet the CNS Penetrant Criteria , (d) any other compounds Covered by any composition of matter claim of a Rigel Patent where such claim Covers Rxxx or any Rxxx Backup, that meet the CNS Penetrant Criteria, or (e ) any pro-drug, salt, free acid form, free base form, hydrate, solvate, polymorph, enantiomer, racemate, amorphous form or co-crystal or other physical form or co-form of (a) through ( d).
View Source
CNS Penetrant or “CNS Penetrance” means, with respect to a small molecule compound: (a) [***]; and (b) [***]. Notwithstanding any provision to the contrary set forth in this Definitive LRRK2 Agreement, the small molecule compounds known as [***] “DNL151” [***] each shall be deemed to be a CNS Penetrant, and the small molecule compounds known as [***] each shall be deemed not to be CNS Penetrant.
View Source
CNS Penetrant means (a) Rxxx, (b) any Rxxx Backup, (c) any compounds Covered by [*] that meet the CNS Penetrant Criteria, (d) any other compounds Covered by any composition of matter claim of a Rigel Patent where such claim Covers Rxxx or any Rxxx Backup, that meet the CNS Penetrant Criteria, or (e) any pro-drug, salt, free acid form, free base form, hydrate, solvate, polymorph, enantiomer, racemate, amorphous form or co-crystal or other physical form or co-form of (a) through (d).
View Source

Examples of CNS Penetrant in a sentence

  • The Development of all CNS Penetrants and CNS Penetrant Products shall be governed by the CNS Penetrant Development Plan.

  • Rigel shall be responsible for the discovery and identification of CNS Penetrants during the CNS Research Term through the delivery to Lilly of the Rxxx Data Package and, if applicable in the case of Rigel Rxxx Continuation, the Rxxx Continuation Data Package, in accordance with the CNS Penetrant Development Plan, at Rigel’s expense.

  • Following the earlier of Rxxx Acceptance and Lilly Rxxx Continuation, Lilly shall be responsible for the Development of CNS Penetrants and CNS Penetrant Products, in accordance with the CNS Penetrant Development Plan, at Lilly’s expense.

  • The conclusions of the Independent Third Party Lab shall be final and binding on the Parties and the Parties shall share equally the costs of any Independent Third Party Lab engaged by a Party pursuant to this Section 14.6.4 (Disputes Regarding LRRK2 Inhibitor or CNS Penetrant).

  • Rigel shall bear one hundred percent (100%) of the costs and expenses incurred by it in connection with the conduct of CNS Penetrant Lead Identification under this Agreement, except, if applicable, in connection with Rigel Rxxx Continuation pursuant to Section 3.4(b) (Rxxx Acceptance).

  • All Compounds and Products with respect to a Terminated Program, i.e., CNS Penetrants and CNS Penetrant Products for the CNS Program and Non-CNS Penetrants and Non-CNS Penetrant Products for the Non-CNS Program, (each, a “Terminated Compound” and “Terminated Product,” respectively) shall cease to be Compounds and Products under this Agreement.

  • In the event of Generic Competition having first occurred in any country, Lilly shall thereafter owe royalties under Section 8.4(a) (Non-CNS Penetrant Products) or 8.4(b) (CNS Penetrant Products), as applicable, on the Net Sales of such Product in such country at rates that are [*] less than the rates otherwise payable under Section 8.4(a) (Non-CNS Penetrant Products) or 8.4(b) (CNS Penetrant Products), as applicable, for the remainder of the Royalty Term.

  • Notwithstanding anything to the contrary in this Agreement, the rights and obligations of Lilly under this Article 5 (Commercialization) with respect to CNS Penetrants and CNS Penetrant Products shall be contingent upon, and shall not take effect until, Rxxx Acceptance.

  • Notwithstanding anything to the contrary in this Agreement, unless the Parties otherwise mutually agree in writing, no amendment to any Development Plan shall materially change the scope of a Party’s Development activities outlined in the initial CNS Penetrant Development Plan or the initial Non-CNS Penetrant Development Plan, as the case may be, nor materially change the allocation of responsibilities between the Parties under any such Development Plan.

  • In the event that, following Generic Competition in such country, a second Generic Equivalent is launched by a Third Party in such country, the foregoing reduction of [*] of the rates otherwise payable under Section 8.4(a) (Non-CNS Penetrant Products) or 8.4(b) (CNS Penetrant Products), as applicable, shall increase to [*], in respect of such country.